NOT YET RECRUITING: NTI164 Rett syndrome trial – Australia

[admin]

Status: Not yet recruitingStudy: Efficacy and safety of NTI164 in children and young adults with Rett syndrome
Registry number: NCT07257978
Country: Australia
Participants: Females aged 4–25 years

What is being studied?
This planned study will evaluate the safety and possible effectiveness of NTI164, a full-spectrum medicinal cannabis plant extract containing a low concentration of THC, in Rett syndrome. The registry lists Monash Children’s Clinical Trial Centre as the contact.

Contact: +61 3 9594 6666 — MonashChildrensCTC@monashhealth.org
Official study record: https://clinicaltrials.gov/study/NCT07257978

Information checked 3 September 2026. Recruitment had not started at the time of checking. Medicinal cannabis can interact with medicines and should only be considered through the study team and the person’s clinician.